Thymosin alpha 1 for use in treatment of cystic fibrosis
AssigneeSciClone Pharmaceuticals International Ltd.
InventorsLuigina Romani, Enrico Garaci
Life of this patent
Estimating the term…
Abstract
The present invention concerns Thymosin alpha 1 for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.
Claims10
A method of treating cystic fibrosis in a patient comprising administering a pharmaceutical composition comprising Thymosin alpha 1 to the patient, wherein the patient has a cystic fibrosis transmembrane conductance regulator (CFTR) mutation ΔF508.
A method of treating cystic fibrosis (CF) in a patient, wherein the patient has a cystic fibrosis transmembrane conductance regulator (CFTR) mutation ΔF508 (ΔF508-CFTR), the method comprises administering a pharmaceutical composition comprising Thymosin alpha 1 to the patient, wherein the treatment is intended to cause one or more effects selected from the group consisting of:
- (1) increasing cell surface expression of ΔF508-CFTR in CF cells of the patient;
- (2) increasing the functional activity of ΔF508-CFTR in CF cells of the patient;
- and
- (3) inducing the expression of alternative ion channel TMEM16A in the patient.
Dependencies are inferred from the claim text.